<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04192994</url>
  </required_header>
  <id_info>
    <org_study_id>END_2019</org_study_id>
    <nct_id>NCT04192994</nct_id>
  </id_info>
  <brief_title>Evaluation do Early Pars Plana Vitrectomy in Acute Endophthalmitis</brief_title>
  <official_title>Evaluation do Early Pars Plana Vitrectomy in Acute Endophthalmitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vinicius Campos Bergamo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nilva Simeren Bueno de Moraes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Luis Filipe Nakayama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Natasha Ferreira Santos da Cruz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Murilo Ubukata Polizelli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study will evaluate the efficacy of early PPV in acute endophthalmitis and attempt to
      prove its greater effectiveness for combating infection when compared to eyes that received
      only intravitreal antibiotic therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endophthalmitis, a severe inflammatory ocular condition with profound visual impairment that
      can lead to irreversible visual loss, requires immediate treatment.

      The only multicenter randomized trial of different forms of acute endophthalmitis treatment
      was the Endophthalmitis Vitrectomy Study. The study concluded that intravitreal antibiotic
      injection improves visual prognosis, and pars plana vitrectomy (PPV) improves the final
      visual acuity (VA) when performed in patients with light perception or worse VA.

      Our study will evaluate the efficacy of early PPV in acute endophthalmitis and attempt to
      prove its greater effectiveness for combating infection when compared to eyes that received
      only intravitreal antibiotic therapy.

      Primary Endpoint: The final VA, ocular anatomy, retinal layer anatomy, and ERG response in
      the intravitreal injection group will be compared with the PPV group.

      Secondary Endpoint: The final VA, eyeball anatomy, retinal layer anatomy, and ERG response in
      the group that underwent PPV will be compared with and without oral moxifloxacin therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group 1: Intravitreal Antibiotic: Group 1a: intravitreal antibiotic isolated; group 1b: intravitreal antibiotic isolated + oral moxifloxacin.
Group 2: PPV: Group 2a: PPV + intraoperative intravitreal antibiotic ; group 2b: PPV + oral moxifloxacin.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Correct Visual Acuity</measure>
    <time_frame>1 year</time_frame>
    <description>The Final Visual acuity will be measured after 1 year</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Anatomy</measure>
    <time_frame>1 year</time_frame>
    <description>The Ocular Anatomy will be evaluated after 1 year, with axial length measured by ocular ultrasound (millimeters)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electroretinography Response (ERG Response)</measure>
    <time_frame>1 year</time_frame>
    <description>The ERG Response will be evaluated after 1 year, measured by Electroretinography (millivolts)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Endophthalmitis</condition>
  <arm_group>
    <arm_group_label>Group 1: Antibiotic injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A total of 0.05 ml of vancomycin 1 mg and 0.05 ml of ceftazidime 2.25 mg will be injected with a 30-gauge needle into the vitreous cavity of the affected eyes in the randomized group, as soon as the diagnosis is confirmed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Pars Plana Vitrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized patients will undergo PPV. Briefly, a blepharostat will be placed followed by instillation of a drop of 5% iodine-povidone over the eye. Under a surgical microscope, three 23-gauge or 25-gauge sclerotomies will be performed. Vitreous core vitrectomy will be performed, and a fluid-gas exchange with balanced saline solution (BSS) or 5,000 grams of silicone oil as a vitreous substitute. At the end of surgery, all sclerotomies will be sutured with Vicryl 7.0 and a total of 0.05 ml of vancomycin 1 mg and 0.05 ml of ceftazidime 2.25 mg will be injected into the vitreous cavity. As soon as the diagnosis is confirmed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Antibiotic Injection</intervention_name>
    <description>Intravitreal Antibiotic Injection</description>
    <arm_group_label>Group 2: Pars Plana Vitrectomy</arm_group_label>
    <other_name>Tap Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pars Plana Vitrectomy</intervention_name>
    <description>Pars Plana Vitrectomy</description>
    <arm_group_label>Group 1: Antibiotic injection</arm_group_label>
    <other_name>PPV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute endophthalmitis with a history of ocular surgical procedures and a
             follow-up time of less than 6 weeks will be included.

        Exclusion Criteria:

          -  Patients with endophthalmitis lasting more than 6 weeks and no history of eye surgery
             will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>18+</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vinicius Campos Bergamo, MD</last_name>
    <phone>(11) 980589798</phone>
    <email>viniciusbergamo.epm@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mauricio Maia, MD, PhD</last_name>
    <phone>5511-5572-6443</phone>
    <email>maiamauricio@terra.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept of Ophthalmology - UNIFESP/Hospital São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04023-062</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinicius Campos Bergamo, MD</last_name>
      <phone>(11) 9 80589798</phone>
      <email>viniciusbergamo.epm@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mauricio Maia, MD, PhD</last_name>
      <phone>5511-5572-6443</phone>
      <email>maiamauricio@terra.com.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 15, 2019</study_first_submitted>
  <study_first_submitted_qc>December 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Mauricio Maia</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endophthalmitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

